Table 1.
Systemic Therapies Currently or Promising Approved for Advanced HCC and ICC
| Drugs | Target | Therapy Line | Approved Year | Trial |
|---|---|---|---|---|
| HCC | ||||
| Sorafenib (Nexavar) | VEGFR-2, VEGFR-3, PDGFR-β, RAF kinases | 1 | 2007 | SHARP Asian-Pacific |
| Lenvatinib (Lenvima) | FGFR, VEGFR, PDGFR-α, RET, KIT | 1 | 2018 | REFLECT |
| Regorafenib (Stivarga) | Tie2, VEGFR, PDGFR, FGFR | 2 | 2017 | RESORCE |
| Nivolumab (Opdivo) | PD-1 | 2 | 2017 | CHECKMATE-040 |
| Cabozantinib (Cabometyx) | c-Met, VEGFR-2, AXL, RET | 2 | 2018 | CELESTIAL |
| Pembrolizumab (Keytruda) | PD-1 | 2 | 2018 | KEYNOTE-224 |
| Ramucirumab (CYRAMZA) | VEGFR-2 | 2 | 2019 | REACH-2 |
| Nivolumab + ipilimumab (Opdivo + Yervoy) | PD-1, CTLA-4 | 2 | 2020 | Cohort 4 of CHECKMATE-040 |
| Atezolizumab + bevacizumab | PD-L1/VEGF | 1 | promising | IMbravel50 |
| Tremelimumab + durvalumab | PD-1, CTLA-4 | 1 | promising | NCT02519348 |
| Donafenib | VEGFR, BRAF | 1 | promising | NCT02645981 |
| Apatinib | VEGFR-2 | 2 | promising | NCT02329860 |
| ICC | ||||
| Gemcitabine + cisplatin | chemotherapy | 1 | 2010 | ABC-02 |
| Pemigatinib (Pemazyre) | FGFR1–3 | 2 | 2020 | FIGHT-202 |
| Ivosidenib | IDH-1/2 | 2 | promising | ClarlDHy |